Prostate cancer is the second leading cause of cancer-related mortality in men. This meta-analysis was conducted to investigate the relationship between race and survival from prostate cancer. A systematic review of articles published from 1968 to 2007 assessing survival from prostate cancer was conducted. Analysis of unadjusted studies reported that African American men have an increased risk of all-cause mortality (hazard ratio [HR] = 1.47, 95% confidence interval [CI] = 1.31-1.65, p < .001). However, examination of adjusted studies identified no difference (HR = 1.07, 95% CI = 0.94-1.22, p = .308). No statistically significant difference was observed in prostate cancer-specific survival in both analyses using unadjusted (HR = 1.11, 95% CI = 0.94-1.31, p = .209) and adjusted studies (HR = 1.15, 95% CI = 0.95-1.41, p = .157). This meta-analysis concludes that there are no racial differences in the overall and prostate cancer-specific survival between African American and White men.
Introduction
Prostate cancer is the most common cancer in men, excluding basal and squamous cell skin cancer. In 2008, approximately 186,320 new cases are estimated to be diagnosed with prostate cancer in the United States (American Cancer Society, 2008) . This estimate accounts for 25% of all the cancers diagnosed in men (American Cancer Society, 2008) . African American men have the highest incidence rates of prostate cancer. The risk of prostate cancer in African Americans is 60% higher than White men (Harris & Lohr, 2002) . Prostate cancer is the second leading cause of cancer-related mortality in men. In the United States, approximately 28,660 men will die from prostate cancer in 2008 alone; accounting for approximately 10% of all the cancers deaths in men (American Cancer Society, 2008) . The mortality rate from prostate cancer is 2.4 times higher in African Americans compared with White men (American Cancer Society, 2007) .
More than 90% of prostate cancers are diagnosed in the local and regional stages, and the 5-year relative survival for these cancers is 100% (American Cancer Society, 2008) . However, the 5-year relative survival for distant prostate cancer is significantly lower (31.9%; American Cancer Society, 2008) . Although overall survival rates are high, rates differ by race; the 5-year survival rates are approximately 7% higher for Whites than African Americans at all stages. The 5-year survival rate for localized prostate cancer is approximately 93% for Whites and 86% for African Americans (Pienta et al., 1995) . Disparity in survival rate is also documented for regional (83% vs. 68%) and metastatic prostate cancers (29% vs. 22%; Pienta et al., 1995) .
Although descriptive studies report that African Americans are disproportionately affected by this disease, compared with Whites, it is not clear if the increased mortality is because of race or factors affecting this population, such as access to care, quality of care, socioeconomic status, stage and grade of tumor, treatment, and comorbidity. Several researchers have attempted to clarify this disparity by controlling for some of the above mentioned confounding factors; however, these studies have produced inconsistent findings (Brawn et al., 1993; Dayal & Chiu, 1982; Dayal, Polissar, & Dahlberg, 1985; Du et al., 2006; Fowler, Bigler, Bowman, & Kilambi, 2000; Gilliland, Hunt, & Key, 1996; Godley et al., 2003; Johnstone et al., 2002; Optenberg et al., 1995; Pienta et al., 1995; Polednak, 2003; Powell et al., 2004; Powell, Schwartz, & Hussain, 1995; Robbins, Whittemore, & Thom, 2000; Robbins, Whittemore, & Van Den Eeden, 1998; Tewari et al., 2005) . Several studies have identified that there is an association between race and survival from prostate cancer (Gilliland et al., 1996; Godley et al., 2003; Pienta et al., 1995; Powell et al., 2004; Robbins et al., 1998; Robbins et al., 2000) , whereas other studies have not identified such an association (Brawn et al., 1993; Dayal & Chiu, 1982; Dayal et al., 1985; Du et al., 2006; Fowler et al., 2000; Johnstone et al., 2002; Optenberg et al., 1995; Polednak, 2003; Powell et al., 1995; Tewari et al., 2005) .
Studies conducted in equal access to care veterans' health systems reported no association between race and survival and have attributed this difference to stage of the disease (Brawn et al., 1993; Powell et al., 1995) . Optenberg et al. (1995) observed that in an equal access Department of Defense medical treatment facility, there was no association between race and survival, but the disparity in survival between African Americans and Whites was explained by stage, grade, and age (Optenberg et al., 1995) . Other studies explained the racial difference in survival with stage and grade of tumor at diagnosis (Fowler et al., 2000; Polednak, 2003) . On the other hand, some studies reported that socioeconomic status may have accounted for most of the differences in survival by race (Dayal & Chiu, 1982; Dayal et al., 1985; Du et al., 2006) . However, all these studies examined socioeconomic status variable at a census tract level but not on an individual level.
A review article by Roach (1998) included studies conducted in the past 15 years and examined five randomized trials on prostate cancer and race. After adjusting for severity of the disease and other confounders, the review concluded that race was not significantly associated with survival. This same study also compared 15 nonrandomized, retrospective, single institution studies that concluded that there was no clear evidence that race independently affects survival from prostate cancer. Furthermore, seven other nonrandomized retrospective studies, with care not delivered at the same institution, suggested that there is a survival difference in outcome by race. As the initial workup, evaluation, and treatment are not uniform compared with the first two sets of studies, the author concluded that race is not an independent prognostic factor for survival (Roach, 1998) .
A review article of 29 articles studying racial differences in prostate cancer treatment outcomes between 1992 and 2002 showed that 79% of the reviewed articles reported no association between race and treatment differences in prostate cancer (Peters & Armstrong, 2005) .
However, several studies have identified that African American patients have poorer survival than White patients and that this difference may be explained by the treatment differences (Alexander & Brawley, 1998; Gilliland et al., 1996; Godley et al., 2003; Johnstone et al., 2002; Tewari et al., 2005) .
Although several observational studies have had conflicting findings, to our knowledge, there are only two meta-analyses conducted examining the impact of race on survival from prostate cancer. Overall survival is defined as death from any cause, and prostate cancer-specific survival is death from prostate cancer as the underlying cause. The first meta-analysis, by Bach et al. in 2002, included 17 studies that examined racial differences in prostate cancer survival between Whites and African Americans who received the same treatment for similar stages of cancer (Bach et al., 2002) . This meta-analysis reported that African Americans had a statistically significant increased risk of mortality from all causes. But this statistical significance disappeared after adjusting for other causes of death derived indirectly from population mortality rates from the National Center for Health Statistics 1997 decennial life tables to account only for cancer-specific mortality. This article examined similar cohorts of men receiving same treatment and similar stages of disease and used indirect adjustment for other causes of death to account for prostate cancerspecific mortality. These results are not generalizable to men with all stages of the disease who are receiving different treatments, and this problem was addressed in the recent meta-analysis by Evans, Metcalfe, Ibrahim, Persad, and Ben-Shlomo (2008) . Evans et al. derived the estimates for prostate cancer-specific mortality directly instead of applying indirect population adjustments. Evans et al. (2008) evaluated 28 studies exploring allcause and prostate cancer-specific mortality as potential outcomes. The study reported increased statistically significant risk for overall survival (hazard ratio [HR] = 1.35, 95% confidence interval (CI) = 1.23-1.48, p < .001) and prostate cancer-specific survival (HR = 1.29, 95% CI = 1.13-1.47, p < .001) among African Americans compared with Whites when using the studies that did not adjust for any confounders or adjusted only for age. When studies that adjusted for age, clinical, and other socioeconomic factors were used, this statistical significance disappeared for the overall survival (HR = 1.01, 95% CI = 0.88-1.16, p = .93); however, prostate cancer-specific survival remained at a marginal increased risk of mortality for African Americans compared with Whites (HR = 1.13, 95% CI = 1.00-1.27, p = .052).
Although this meta-analysis included all the key articles, there was a major methodological drawback. The authors have included more than one article from the same SEER cancer registry data, which represented overlapping time periods and included the same SEER location (San Francisco Bay region) for prostate cancer-specific mortality (Du et al., 2006; Oakley-Girvan et al., 2003; Polednak, 2003; Robbins et al., 2000) . When the metaanalysis was repeated after removing the two SEER articles, namely, Du et al. (2006) and Polednak (2003) , the increased risk was not statistically significant (HR = 1.14, 95% CI = .95-1.36, p = .15; CI and p value obtained through communication with the author). However, the article did not discuss this crucial information and reported increased risk among African American men for prostate cancer-specific mortality (Evans et al., 2008) .
We conducted a meta-analysis of studies that exclusively address the impact of race, not just as a primary exposure variable but also as one of the potential independent variables, on survival in men for localized and advanced prostate cancer. This meta-analysis mitigates the limitations in the previous meta-analyses (Bach et al., 2002; Evans et al., 2008) . Recognizing the varied nature of the studies in terms of standard errors, sample sizes, and adjustments for potential confounding variables, this study used two distinct methodologies to examine the association between race and survival from prostate cancer.
Materials and Methods

Study Selection
A Medline/PubMed search of published articles in English from 1968 to 2007 was performed. Keywords and MESH terms including terms such as prostate cancer, survival, mortality, and race were used. Three levels of screening to select relevant publications for this analysis were used. First, two independent reviewers examined all the identified abstracts to find relevant publications using the criteria that included race as the primary exposure variable, or at least one of the covariates, and survival, either overall or prostate cancer-specific survival, as the outcome. Second, each relevant publication was examined thoroughly to determine that the inclusion criteria were fulfilled. Additionally, the reference section of the selected relevant publications was examined for additional publications that were missed in the initial search. Third, the selected publications were reviewed and abstracted. At this stage, publications from the same data sources, place, and overlapping time periods were identified and it was made sure that only one publication was selected.
Inclusion and Exclusion Criteria
The inclusion criteria for this meta-analysis included original research articles that (a) were published between 1968 and 2007; (b) had race, specifically Whites and African Americans, as the main exposure variable or covariate; (c) had overall survival or prostate cancer-specific survival as one of the outcome variables; and (d) provided estimates from which log HRs and standard errors can be calculated directly or indirectly. Only articles published in English were selected. Review articles or letters were not included in this analysis. Articles that either compared Blacks with non-Blacks or non-Whites with Whites were also excluded from the analysis to ensure comparisons only between Whites and Blacks.
When there were several publications from the same data source, such as the SEER cancer registry data, with overlapping time frames and locations, only one publication was selected to be included in the analysis. This was done to ensure that too much weight was not given to articles that include the same data and skew the summary estimate. Factors such as the most recent year of publication, larger sample size, number and types of confounders examined, longer follow-up period, and inclusion of relevant effect sizes were considered to select publications. Although the initial search yielded 505 publications, only 20 articles met the inclusion criteria for this analysis (Figure 1 ). Detailed descriptions of the selected studies are included in the appendix (See Appendix A).
Out of the 20 publications, 17 studies provided estimates for overall survival (Aziz et al., 1988; Berry, Laszlo, Cox, Walker, & Paulson, 1979; Brawn et al., 1993; Crawford et al., 1990; Dayal & Chiu, 1982; Dayal et al., 1985; Du et al., 2006; Freeman et al., 2004; Halabi, Vogelzang, Ou, Kelly, & Small, 2006; Hussain, Aziz, Macchia, Avitable, & Rotman, 1992; Kim, Kuban, el-Mahdi, & Schellhammer, 1995; Optenberg et al., 1995; Powell et al., 1995; Roach et al., 2003; Tewari et al., 2006; Thompson et al., 2001; Zagars, Pollack, & Pettaway, 1998) . Thirteen articles had estimates available to calculate the crude overall survival HRs and 95% CIs directly (2 studies; Roach et al., 2003; Thompson et al., 2001) or indirectly from Kaplan-Meier survival curves (11 studies; Aziz et al., 1988; Berry et al., 1979; Brawn et al., 1993; Crawford et al., 1990; Dayal & Chiu, 1982; Du et al., 2006; Hussain et al., 1992; Kim et al., 1995; Optenberg et al., 1995; Powell et al., 1995; Zagars et al., 1998) . Eight articles had estimates available to calculate the adjusted overall survival HRs and 95% CIs directly (Dayal et al., 1985; Du et al., 2006; Freeman et al., 2004; Halabi et al., 2006; Optenberg et al., 1995; Roach et al., 2003; Tewari et al., 2006; Thompson et al., 2001) . Prostate cancer-specific survival was reported in 9 articles (Du et al., 2006; Fowler et al., 2000; Freeman et al., 2004; Halabi et al., 2006; Hart et al., 1998; Iselin et al., 1998; Kim et al., 1995; Roach et al., 2003; Tewari et al., 2006) . Six articles had estimates available to calculate the crude HRs and 95% CIs for prostate cancer-specific survival directly (2 studies; Iselin et al., 1998; Roach et al., 2003) or indirectly from Kaplan-Meier survival curves (4 studies; Du et al., 2006; Fowler et al., 2000; Hart et al., 1998; Kim et al., 1995) . Seven articles had estimates available to calculate the adjusted HRs and 95% CIs for prostate cancer-specific survival directly (Du et al., 2006; Fowler et al., 2000; Freeman et al., 2004; Halabi et al., 2006; Iselin et al., 1998; Roach et al., 2003; Tewari et al., 2006) . Some studies provided both unadjusted and adjusted estimates, whereas others reported only the unadjusted or adjusted effect sizes.
Data Abstraction
Data abstraction form was developed, and two independent reviewers abstracted relevant information from the selected publications. Information including bibliographic information (authors, title, journal of publication, date, and whether peer reviewed or not), study setting (study location, type, name, and data source), study population characteristics (age, race, stage, and grade of cancer), study design details (sample size, year of prostate cancer diagnosis, length of follow-up), model characteristics (exposure variable, outcome variable, other covariates assessed and controlled for confounders), and study results (HRs and 95% CIs or p values from Cox proportional hazard regression, Kaplan-Meier survival curves) were abstracted. There was 70% agreement between the two abstractors, and conflicts between the two abstractors were resolved by a third reviewer who conducted a blinded review of the article.
Statistical Analysis
The selected publications reported different estimates for the association between race and survival, including HRs and 95% CIs or p values from Cox proportional hazard regression or Kaplan-Meier survival curves. Log HRs and standard errors were used to calculate the summary HRs and 95% CIs. The method described by Parmar, Torri, and Stewart (1998) was used to derive the log HRs and standard errors directly for the articles providing HRs and 95% CIs or p values. The log HRs and standard errors were determined indirectly for the crude analysis using Parmar et al.'s method and Microsoft Excel spreadsheets provided by Tierney Stewart, Ghersi, Burdett, and Sydes (2007) from Kaplan-Meier survival curves. Depending on the results of the tests for heterogeneity, including Q statistic and I 2 statistic, a decision was made whether to use fixed effects or Dersimonian-Laird random effects model. As the tests for heterogeneity was significant in all the analyses, random effects model results are reported.
To account for the differences among the studies in terms of standard errors, sample size, and adjustment for confounders, weighted analysis was considered. Weighting the studies with respect to standard errors is straightforward. In addition to this, weighting the studies according to their other characteristics that are considered important in public health studies was also considered. Previous publications have provided mixed opinions on whether quality scoring should be used as a weighting variable. Some articles comment that quality scoring adds subjective bias and may lack validity, and results may not represent quality (Bonovas, Filioussi, & Sitaras, 2006; Greenland, 1994; Juni, Witschi, Bloch, & Egger, 1999; Stroup et al., 2000) . Other studies claim that quality scoring can be done but recommend not using the scores as weights but rather using the summary score as a covariate to conduct subgroup and sensitivity analysis (Berman & Parker, 2002; Friedenreich, Brant, & Riboli, 1994; Stroup et al., 2000) . As suggested in the literature, this study used standard error as weighting variable and investigated if the analysis Medline search "prostate cancer", "survival", "mortality" and "race" using summary score as weighting variable also holds true with this analysis. These two distinct methods were considered to maximize the validity of this meta-analysis.
To preserve objectivity of the scoring, only the factors that are important predictors of prostate cancer and those that do not pose any scoring ambiguity, such as age of the patient, stage of the disease, grade of the tumor, treatment, comorbidity, socioeconomic status, prebiopsy prostatespecific antigen levels, and sample size of the study were considered. Studies that adjust for confounders and have larger sample size provide valid information about the racial differences than those that do not, and therefore, these studies with adjusted analysis received a higher weight. If a study adjusted for potential confounders it was given a score of 1 for each confounder, otherwise a 0 score was assigned. Similarly if a study had a sample size more than 1,000, then a score of 1 was assigned, otherwise a 0 score was given. Then, a sum of these scores was obtained and weights were assigned proportional to the inverse of these scores for each study that provided the quality scores. Proportional weights were then assigned according to the standard error of each study. Finally, an average of the first and the second weight was taken, which was used in the analysis as a weighting variable instead of just using the standard error of the study. Therefore, a study with higher score received a higher weight.
Two independent researchers scored these studies so that reliability could be established. The analysis was then performed in two ways: first with weights obtained from standard errors alone, then by using summary weights that are averages of the weights based on the standard errors and the weights based on the quality scores.
Funnel plots were used to examine publication bias. Sensitivity analysis was performed to determine robustness of the meta-analysis. To examine the effects of small and outlier studies, we removed one study at a time and repeated the analysis with the remaining studies. Further subgroup and meta-regression analyses were done on selected covariates to identify potential explanations for heterogeneity among studies. All analyses were done using STATA Statistical software Version 10.1 (StataCorp, College Station, Texas). All p values were two-sided, and values less than .05 were considered significant.
Results
The findings of this meta-analysis are presented into two main sections: (a) overall survival and (b) prostate cancerspecific survival.
Overall Survival
Unadjusted and adjusted summary estimates using standard error as weights. Pooled estimate from the 13 studies with unadjusted estimates identified a statistically significant increased risk of mortality among African American men compared with White men (HR = 1.47, 95% CI = 1.31-1.65, p < .001). However, no statistically significant difference was observed in the analysis using the adjusted HRs from the eight studies that adjusted for age, clinical, and other demographic variables (HR = 1.07, 95% CI = 0.94-1.22, p = .308). Figure 2 shows that there was evidence of heterogeneity among the studies in the adjusted analysis (Q = 36.45, df = 7, p < .001).
Adjusted summary estimates using summary score as weights. Using summary score as weights evenly distributed the weights among the studies compared with using standard error as weights. Conversely, the summary estimates from the eight adjusted studies remained the same (HR = 1.06, 95% CI = 0.90, 1.25, p = .463) compared with the pooled estimates obtained using standard error as weights. Table 1 compares the summary estimates derived from the standard error and summary score methods for the unadjusted, adjusted, and overall analyses. The findings from the two methods were fairly similar and comparable.
Publication bias. Figure 3 shows equal dispersion of studies. Both the unadjusted and adjusted models identified no evidence of publication bias in the funnel plots.
Sensitivity analysis. Small studies and potential outliers were identified using standard errors and funnel plots. These studies were removed one at a time, and the summary estimates were evaluated each time. In the unadjusted analysis, removal of the following small studies and outliers provided the following estimates: Eliminating all three studies at the same time yielded similar results as the overall unadjusted analysis (HR = 1.35, 95% CI = 1.29-1.41, p < .001).
In the adjusted analysis, removing the following studies resulted in the following estimates: Halabi et al. (2006;  HR = 1.12, 95% CI = 0.99-1.28, p = .069), Freeman et al.
(HR = 1.02, 95% CI = 0.91-1.14, p = .745), and Optenberg et al. (HR = 1.10, 95% CI = 0.97-1.25, p = .155). Excluding all the three articles at the same time produced similar results as the overall adjusted analysis (HR = 1.08, 95% CI = 1.00-1.17, p = .065).
Subgroup and meta-regression analysis. Subgroup and meta-regression analyses were conducted across several covariates to explain the heterogeneity among the studies (Tables 2 and 3 ). The analyses identified that the heterogeneity observed among the studies examining overall survival cannot be explained by any of the covariates including stage, recruitment year, or study type.
Prostate Cancer-Specific Survival
Unadjusted and adjusted summary estimates using standard error as weights. Evaluation of the six studies with unadjusted estimates identified no statistically significant excess risk of prostate cancer-specific mortality among African American men compared with White men (HR = 1.11, 95% CI = 0.94-1.31, p = .209). Similarly, analysis of the seven studies with the adjusted estimates also identified no increased risk among African American men compared with White men (HR = 1.15, 95% CI = 0.95-1.41, p = .157). Further examination of these studies reported evidence of heterogeneity among the studies in the adjusted analysis (Q = 22.46, df = 6, p = .001; Figure 4 ).
Adjusted summary estimates using calculated summary score as weights. A modest difference in weights occurred when quality scores were added to the weights obtained from standard errors, compared with the weights from standard error alone. The pooled estimates from the seven adjusted studies did not change (HR = 1.17, 95% CI = 0.96-1.43, p = .113) compared with the estimates obtained using standard error as weights. Summary estimates derived from the standard error and summary score methods yielded consistent findings for the unadjusted, adjusted, and overall analysis (Table 4) .
Publication bias. Funnel plots showed equal dispersion of studies and no evidence of publication bias in both unadjusted and adjusted models ( Figure 5) . Note: CI = confidence interval. All p values are two-tailed. p = .004) in the subgroup analysis and by metastatic stage in the meta-regression analysis (Tables 5 and 6 ).
Discussion
This study identified no statistically significant increased risk of mortality from all causes and prostate cancerspecific causes in African American men compared with White men. These results were consistent with the observations made by Bach et al. (2002) who reported no increased risk in African Americans compared with Whites for prostate cancer-specific survival. Although the overall survival results of this study was consistent to the findings observed by Evans et al. (2008) , inconsistency between the two studies was observed in the prostate .08, 95% CI = 0.90-1.31, p = .395), and both articles at the same time (HR = 1.18, 95% CI = 1.06-1.32, p = .003) resulted in statistically significant estimates compared with the summary estimates obtained in the pooled adjusted analysis.
Subgroup and meta-regression analyses. The heterogeneity among the studies examining the association between race and prostate cancer-specific survival can be explained by stage of the disease including local/regional (HR = 1.17, 95% CI = 1.04-1.32, p = .009), metastatic (HR = 0.76, 95% CI = 0.63-0.92, p = .005), recruitment period in 1987 or earlier (HR = 1.19, 95% CI = 1.02-1.38, p = .026), and retrospective cohort study types (HR = 1.22, 95% CI = 1.07-1.39, cancer-specific mortality. Evans et al. reported increased risk in prostate cancer-specific survival, whereas this study observed no increased risk.
The major reason for this discrepancy in the prostate cancer-specific survival analysis between these studies may be because of the differences in article selection. This meta-analysis only included one article from the SEER cohort that spanned across all 11 SEER sites, is most recent, had a large sample size, and was comprehensive (Du et al., 2006) . However, Evans et al. (2008) used four studies from the SEER cohorts that not only had overlapping time periods but also included the San Francisco Bay region (Table 7; Du et al., 2006; Oakley-Girvan et al., 2003; Polednak, 2003; Robbins et al., 2000) . When Evans et al. (2008) conducted sensitivity analysis and excluded Du et al. (2006) and Polednak et al. (2003) from the prostate cancer-specific survival analysis, they also observed no increased risk (HR = 1.14, 95% CI = 0.95-1.36, p = .15; CI and p values obtained through communication with the author), consistent with our analysis.
This article excluded some studies because of the inclusion/exclusion criteria for reasons including estimates not available (Jones et al., 1995; Khuntia, Reddy, Mahadevan, Klein, & Kupelian, 2004; McLeod et al., 1999) . Additionally, this study included only one publication and excluded additional publications from University of Texas MD Anderson Cancer Center (Wyatt et al., 2004) and SEER cohorts (Godley et al., 2003; Oakley-Girvan et al., 2003; Polednak, 2003; Robbins et al., 2000) . Unlike other studies, this meta-analysis has several strengths. It addresses and accounts for serious methodological flaws observed in other studies. The study excluded more than one article from the SEER registry data with overlapping time periods and only included one publication from the SEER registry data. Additionally, this study evaluated all published articles from 1968 to 2007 and excluded those not meeting the inclusion criteria compared with the earlier meta-analyses. Only eight and seven adjusted studies met the inclusion criteria for the overall and prostate cancer-specific survival, respectively. This is not uncommon in a meta-analysis of this nature, as most of the studies use data from the same SEER registry or hospital records and only articles with nonoverlapping data had to be included in the final analysis.
The limitations of this study include the fact that it only includes published articles from 1968 to 2007. This excludes unpublished studies, and usually unpublished studies are more likely to show negative results. Therefore, this study may be overestimating the summary HRs because of the exclusion of those articles. However, the tests identified no evidence of publication bias. In the adjusted analysis, there was evidence for heterogeneity that was accounted for by performing random effects modeling, subgroup analysis, and meta-regression analysis. However, the potential still exists for a lack of homogeneity among all the studies used to produce the summary HRs. This study only included studies that compared Blacks and Whites and did not include the studies that compared Whites with non-Whites or Blacks with non-Blacks. This was done to ensure a precise comparison between Blacks and Whites. Non-Blacks or non-Whites may include groups that are likely to have better or worse survival and bias the study.
In conclusion, there are no differences between African American and Whites in survival from prostate cancer. Future studies including prospective cohort studies and clinical trials are needed to study the racial disparity in prostate cancer survival. Most of the existing data are based on analyses from the SEER registry data and hospital records data using retrospective cohort study design. Additional recent study data that meet the inclusion criteria should be added to the existing studies in this meta-analysis, and this important question of racial disparity between African Americans and Whites in prostate cancer survival needs to be evaluated. 
